Aysegul Sahin
Overview
Explore the profile of Aysegul Sahin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
4937
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Abuhadra N, Sun R, Yam C, Rauch G, Ding Q, Lim B, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444385
High stromal tumor-infiltrating lymphocytes (sTILs) are associated with improved pathologic complete response (pCR) in triple-negative breast cancer (TNBC). We hypothesize that integrating high sTILs and additional clinicopathologic features associated with...
12.
Cho W, Ding Q, Wang W, Nagarajan P, Curry J, Torres-Cabala C, et al.
J Cutan Pathol
. 2023 Feb;
50(5):434-440.
PMID: 36808637
Background: Trichorhinophalangeal syndrome type 1 (TPRS1) expression has been found to be highly sensitive and specific for breast carcinomas. The frequency of TRPS1 expression in cutaneous neoplasms such as mammary...
13.
Liang D, Black D, Yi M, Luo C, Singh P, Sahin A, et al.
Ann Surg Oncol
. 2022 Mar;
PMID: 35298763
No abstract available.
14.
Yoon E, Ding Q, Hunt K, Sahin A
Surg Pathol Clin
. 2022 Mar;
15(1):77-93.
PMID: 35236635
Most of the high-grade spindle cell lesions of the breast are malignant phyllodes tumors (MPTs), spindle cell carcinomas (SpCCs), and matrix-producing metaplastic breast carcinomas (MP-MBCs). MPTs have neoplastic spindle stromal...
15.
Liang D, Black D, Yi M, Luo C, Singh P, Sahin A, et al.
Ann Surg Oncol
. 2022 Mar;
29(6):3822-3828.
PMID: 35233742
Background: Nonpalpable breast lesions require precise preoperative localization to facilitate negative margins with breast-conserving therapy. The traditional use of wires has several challenges including patient discomfort, wire migration, and coordination...
16.
Akcakanat A, Zheng X, Cruz Pico C, Kim T, Chen K, Korkut A, et al.
Clin Cancer Res
. 2021 Mar;
27(11):3243-3252.
PMID: 33782032
Purpose: Metastatic breast cancer (MBC) is not curable and there is a growing interest in personalized therapy options. Here we report molecular profiling of MBC focusing on molecular evolution in...
17.
Tan P, Ellis I, Allison K, Brogi E, Fox S, Lakhani S, et al.
Histopathology
. 2020 Feb;
77(2):181-185.
PMID: 32056259
No abstract available.
18.
Karakas C, Francis A, Ha M, Wingate H, Meena R, Yi M, et al.
Ann Surg
. 2019 Aug;
274(2):e150-e159.
PMID: 31436549
Background: Pathologic complete response (pCR) has been shown to be associated with favorable outcomes in breast cancer. Predictors of pCR could be useful in guiding treatment decisions regarding neoadjuvant therapy....
19.
Xing Y, Lin N, Maurer M, Chen H, Mahvash A, Sahin A, et al.
Breast Cancer Res
. 2019 Jul;
21(1):78.
PMID: 31277699
Background: The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 in...
20.
Kettner N, Vijayaraghavan S, Guray Durak M, Bui T, Kohansal M, Ha M, et al.
Clin Cancer Res
. 2019 Mar;
25(13):3996-4013.
PMID: 30867218
Purpose: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are currently used in combination with endocrine therapy to treat advanced hormone receptor-positive, HER2-negative breast cancer. Although this treatment doubles time to progression compared...